Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone Health, New York, NY, tells us about the poor prognosis many multiple myeloma patients receive and the benefits of molecular techniques such as the use of daratumumab and IMiDs at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.